Skip to main content

Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design.

Publication ,  Journal Article
Hess, KR; Abbruzzese, JL
Published in: J Clin Oncol
August 1, 2001

Duke Scholars

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

August 1, 2001

Volume

19

Issue

15

Start / End Page

3445 / 3446

Location

United States

Related Subject Headings

  • Randomized Controlled Trials as Topic
  • Pancreatic Neoplasms
  • Oncology & Carcinogenesis
  • Matrix Metalloproteinase Inhibitors
  • Hydroxamic Acids
  • Humans
  • Enzyme Inhibitors
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hess, K. R., & Abbruzzese, J. L. (2001). Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design. J Clin Oncol, 19(15), 3445–3446. https://doi.org/10.1200/JCO.2001.19.15.3445
Hess, K. R., and J. L. Abbruzzese. “Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design.J Clin Oncol 19, no. 15 (August 1, 2001): 3445–46. https://doi.org/10.1200/JCO.2001.19.15.3445.
Hess, K. R., and J. L. Abbruzzese. “Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design.J Clin Oncol, vol. 19, no. 15, Aug. 2001, pp. 3445–46. Pubmed, doi:10.1200/JCO.2001.19.15.3445.

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

August 1, 2001

Volume

19

Issue

15

Start / End Page

3445 / 3446

Location

United States

Related Subject Headings

  • Randomized Controlled Trials as Topic
  • Pancreatic Neoplasms
  • Oncology & Carcinogenesis
  • Matrix Metalloproteinase Inhibitors
  • Hydroxamic Acids
  • Humans
  • Enzyme Inhibitors
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences